Long ago, Aristotle, Aquinas and other thinkers
concluded that, as a moral necessity, the price of things must reflect their
actual worth. They wrote that the actual
price charged for a thing must be its “just price.” Surely Adam Smith, himself a moral
philosopher, knew that as he unveiled his new science of Economics. His great failure though, and it was great
and it was a failure indeed, was to introduce “the invisible hand of the market” to wash away all
sin. That worked in 18th century
Scotland, a classic traditional “small market” economy”, but somehow has lost
its cleansing power in our 21st century age. Smith’s assumption of buyer and sellers with
common moral norms getting together under conditions where each knows fairly
well the “just price” that should be charged, and by their decisions help set
it, no longer is even close to describing our current economy. Modern economists see only “all the market
will bear” as the criterion for price, and justice has nothing to do with it.
That comes to mind in reading a Washington Post
article on the cost of cancer drugs, written by three distinguished
oncologists, Hagop Kantarjian, Tito Fojo and Leonard Zwelling. They ask why 11 of the 12 new cancer drugs
approved by the FDA last year each have an estimated annual cost of over
$100,000, yet only 3 of the 12 actually improve survival rates, and then only
in minimal ways. They note that the
average monthly cost of cancer drugs has more than doubled in the past 5 years
(this, in a time of recession!). They
delve in their article into moral issues specific to oncology, such as whether
price should be based on survival rates or actual effects on tumors, but raise
broader issues also. For example, the
usual justification by drug companies for their charges is “product development
costs”, including costs of testing unsuccessful drugs, but it also includes
items like education (we all know about those physician “seminars” in the
Caribbean and Hawaii included in that) and advertizing. The internal pricing each company arrives at
for those items is arbitrary and varies a lot company to company. Is it just to bill a dying patient for physician
jaunts to Hawaii? And companies “pay to
delay” the entrance of cheaper generic drugs into the market. Should patients bear the cost of that?
But here’s the really big item. The VA gets drugs at half the price of
Medicare because the VA is allowed to negotiate price but Medicare is
prohibited. As a result, the prices
Medicare must pay for are two to four times the prices charged for the same
drug in other countries. Those are not
drugs from the cheap fly-by-night outfits the drug companies rail about, but
the prices paid to the same U.S. companies that are doing the railing. Unchaining the market to wave its invisible
hand would bring remarkable reductions in the cost of drugs, but of course that’s
not all that’s needed. Medicare
negotiating would be an enormous gain for the economy and the patient, but
would still leave the patient ignorant and feeble amid the pressures big
pharmaceutical companies can exert. Much
stronger investigation and regulation of the claims companies make for efficacy
of their drugs is required, along with strong regulation of the cost accounting
that goes into setting prices. In the EU
regulators approve drug prices, and costs are substantially lower; in the U.S.,
such prices are unregulated. The FDA
responsibility should be expanded to include medicine price regulation.
All our politicians speak of the need to reduce
the cost of Medicare. Too many of them
speak as though it’s a matter of reducing eligibility and coverage. In fact, the biggest savings are available
without any reduction in service. In
other countries, a moral principle of health care is that no one should unduly
profit off the sickness of others. They
provide excellent health care at reasonable prices, guided by that
principle. For the U.S. to address “morally
acceptable prices” for medicines would be a major step in that direction.